SCHEMBL6138539

SCHEMBL6138539

O=C(CCCCC(O)c1ccc(C2CCCC2)cc1)NO

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 5/20 0.52
HDAC1 Q13547 4/20 0.52
HDAC6 Q9UBN7 5/20 0.47
ALDH1A1 P00352 1/20 0.46
HDAC2 Q92769 3/20 0.43
HDAC3 O15379 3/20 0.43
HDAC11 Q96DB2 3/20 0.43
HDAC10 Q969S8 2/20 0.43
NCOR2 Q9Y618 1/20 0.43
PTGER2 P43116 8/20 0.40
PTGER4 P35408 2/20 0.40
PTGER3 P43115 2/20 0.40
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138450 0.99 HDAC1 (0.51) HDAC8HDAC1HDAC6ALDH1A1HDAC2
SCHEMBL6138895 0.99 HDAC1 (0.51) HDAC8HDAC1HDAC6ALDH1A1HDAC2
SCHEMBL6139008 0.99 HDAC1 (0.51) HDAC8HDAC1HDAC6ALDH1A1HDAC2
SCHEMBL6138998 0.99 HDAC1 (0.51) HDAC8HDAC1HDAC6ALDH1A1HDAC2
SCHEMBL6138792 0.90 HDAC1 (0.50) HDAC8HDAC1HDAC6HDAC2HDAC3
SCHEMBL6138787 0.90 HDAC1 (0.50) HDAC8HDAC1HDAC6HDAC2HDAC3
SCHEMBL6138559 0.86 HDAC1 (0.47) HDAC8HDAC1HDAC6ALDH1A1HDAC2
SCHEMBL6138563 0.86 HDAC1 (0.47) HDAC8HDAC1HDAC6ALDH1A1HDAC2
Hydrochloric Acid SCHEMBL6138981 0.85 HDAC1 (0.46) HDAC8HDAC1HDAC6ALDH1A1HDAC2
SCHEMBL6138785 0.85 ALDH1A1 (0.51) HDAC8HDAC1HDAC6ALDH1A1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP claimed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US claimed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP claimed
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP disclosed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US disclosed
US-6770644-B1 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient ONO PHARMACEUTICALS CO., LTD. (JP) 2004-08-03 US disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient HIF1AN, IL6, PYGM HDAC8 1134/4885HDAC1 942/4885HDAC6 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.